Brainomix

Exciting news for the health tech sector! 🚀 Oxford-based Brainomix, a pioneer in AI imaging tools for stroke and lung fibrosis, has successfully extended its Series C round with a fresh £4.8 million investment. This significant capital injection boosts their total Series C funding to £18.8 million, marking a robust vote of confidence in their innovative technology. This crucial funding will fuel Brainomix's strategic expansion, particularly bolstering its US operations and accelerating the deployment of its groundbreaking AI imaging platforms, Brainomix 360 Stroke and e-Lung, across more hospitals. We are thrilled to see Brainomix continue its mission to transform patient care with solutions that enhance rapid stroke assessment and early identification of fibrosing lung diseases. The extension was led by existing investors Parkwalk Advisors and Hostplus (via IP Group Hostplus Innovation Fund), with new participation from Modi Ventures. Congratulations to the entire Brainomix team on this impressive milestone! We look forward to witnessing their continued impact in improving clinical decision-making and patient outcomes globally. #HealthTech #VCFunding #AIinHealthcare #MedTech